ACS Medicinal Chemistry Letters
Letter
(13) Uddin, M. J.; Crews, B. C.; Blobaum, A. L.; Kingsley, P. J.;
Gorden, D. L.; McIntyre, J. O.; Matrisian, L. M.; Subbaramaiah, K.;
Dannenberg, A. J.; Piston, D. W.; Marnett, L. J. Selective visualization
of cyclooxygenase-2 in inflammation and cancer by targeted
fluorescent imaging agents. Cancer Res. 2010, 70, 3618−3627.
(14) Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Huda, I.; Kingsley,
P. J.; Ansari, M. S.; Tantawy, M. N.; Reese, J.; Marnett, L. J.
Fluorinated COX-2 inhibitors as agents in PET imaging of
inflammation and cancer. Cancer Prev. Res. 2011, 4, 1536−1545.
(15) Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Marnett, L. J.
Design, synthesis, and structure-activity relationship studies of
fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging
agents. Bioconjugate Chem. 2013, 24, 712−723.
AUTHOR INFORMATION
Corresponding Author
*Phone: 615-343-7329. Fax: 615-343-7534. E-mail: larry.
■
Author Contributions
The manuscript was written through contributions of all
authors. All authors have given approval to the final version of
the manuscript.
Funding
This study is supported by research grants from the National
Institutes of Health (CA89450, CA136465, and S10
RR019022).
(16) Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Tantawy, M. N.;
Marnett, L. J. [I]-Celecoxib analogues as SPECT tracers of
cyclooxygenase-2 in inflammation. ACS Med. Chem. Lett. 2011, 2,
160−164.
Notes
The authors declare no competing financial interest.
(17) Perrone, M. G.; Malerba, P.; Uddin, M. J.; Vitale, P.; Panella, A.;
Crews, B. C.; Daniel, C. K.; Ghebreselasie, K.; Nickels, M.; Tantawy,
M. N.; Manning, H. C.; Marnett, L. J.; Scilimati, A. PET radiotracer
[(1)(8)F]-P6 selectively targeting COX-1 as a novel biomarker in
ovarian cancer: preliminary investigation. Eur. J. Med. Chem. 2014, 80,
562−568.
(18) Teng, X. W.; Abu-Mellal, A. K.; Davies, N. M. Formulation
dependent pharmacokinetics, bioavailability and renal toxicity of a
selective cyclooxygenase-1 inhibitor SC-560 in the rat. J. Pharm.
Pharm. Sci. 2003, 6, 205−210.
(19) Fukai, R.; Zheng, X.; Motoshima, K.; Tai, A.; Yazama, F.;
Kakuta, H. Design and synthesis of novel cyclooxygenase-1 inhibitors
as analgesics: 5-amino-2-ethoxy-N-(substituted-phenyl)benzamides.
ChemMedChem 2011, 6, 550−560.
(20) Kakuta, H.; Zheng, X.; Oda, H.; Harada, S.; Sugimoto, Y.;
Sasaki, K.; Tai, A. Cyclooxygenase-1-selective inhibitors are attractive
candidates for analgesics that do not cause gastric damage. design and
in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1
selective inhibitor. J. Med. Chem. 2008, 51, 2400−2411.
(21) Liedtke, A. J.; Crews, B. C.; Daniel, C. M.; Blobaum, A. L.;
Kingsley, P. J.; Ghebreselasie, K.; Marnett, L. J. Cyclooxygenase-1-
selective inhibitors based on the (E)-2′-des-methyl-sulindac sulfide
scaffold. J. Med. Chem. 2012, 55, 2287−2300.
(22) Calvello, R.; Panaro, M. A.; Carbone, M. L.; Cianciulli, A.;
Perrone, M. G.; Vitale, P.; Malerba, P.; Scilimati, A. Novel selective
COX-1 inhibitors suppress neuroinflammatory mediators in LPS-
stimulated N13 microglial cells. Pharmacol. Res. 2012, 65, 137−148.
(23) Di Nunno, L.; Vitale, P.; Scilimati, A.; Tacconelli, S.; Patrignani,
P. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib:
reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J.
Med. Chem. 2004, 47, 4881−4890.
(24) Imanishi, J.; Morita, Y.; Yoshimi, E.; Kuroda, K.; Masunaga, T.;
Yamagami, K.; Kuno, M.; Hamachi, E.; Aoki, S.; Takahashi, F.;
Nakamura, K.; Miyata, S.; Ohkubo, Y.; Mutoh, S. Pharmacological
profile of FK881(ASP6537), a novel potent and selective cyclo-
oxygenase-1 inhibitor. Biochem. Pharmacol. 2011, 82, 746−754.
(25) Kusuhara, H.; Fukunari, A.; Matsuyuki, H.; Okumoto, T.
Principal involvement of cyclooxygenase-1-derived prostaglandins in
the c-fos expression of the rat hind brain following visceral stimulation
with acetic acid. Brain Res. Mol. Brain Res. 1997, 52, 151−156.
(26) Ochi, T.; Motoyama, Y.; Goto, T. The analgesic effect profile of
FR122047, a selective cyclooxygenase-1 inhibitor, in chemical
nociceptive models. Eur. J. Pharmacol. 2000, 391, 49−54.
ACKNOWLEDGMENTS
■
Spectroscopic analysis of all new molecules was conducted in
the Small Molecule NMR Facility and Mass Spectrometry
Research Center at the Vanderbilt Institute of Chemical
Biology.
ABBREVIATIONS
COX, cyclooxygenase; PET, positron emission tomography;
TLC, thin layer chromatography
■
REFERENCES
■
(1) Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases:
structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000,
69, 145−182.
(2) Vanhoutte, P. M. COX-1 and vascular disease. Clin. Pharmacol.
Ther. 2009, 86, 212−215.
(3) Choi, S. H.; Aid, S.; Bosetti, F. The distinct roles of
cyclooxygenase-1 and -2 in neuroinflammation: implications for
translational research. Trends Pharmacol. Sci. 2009, 30, 174−181.
(4) Erovic, B. M.; Woegerbauer, M.; Pammer, J.; Selzer, E.; Grasl, M.;
Thurnher, D. Strong evidence for up-regulation of cyclooxygenase-1 in
head and neck cancer. Eur. J. Clin. Invest. 2008, 38, 61−66.
(5) Hwang, D.; Scollard, D.; Byrne, J.; Levine, E. Expression of
cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J.
Natl. Cancer Inst. 1998, 90, 455−460.
(6) Kirschenbaum, A.; Klausner, A. P.; Lee, R.; Unger, P.; Yao, S.;
Liu, X. H.; Levine, A. C. Expression of cyclooxygenase-1 and
cyclooxygenase-2 in the human prostate. Urology 2000, 56, 671−676.
(7) Cho, M.; Kabir, S. M.; Dong, Y.; Lee, E.; Rice, V. M.; Khabele,
D.; Son, D. S. Aspirin blocks EGF-stimulated cell viability in a COX-1
dependent manner in ovarian cancer cells. J. Cancer 2013, 4, 671−678.
(8) Daikoku, T.; Tranguch, S.; Chakrabarty, A.; Wang, D.; Khabele,
D.; Orsulic, S.; Morrow, J. D.; Dubois, R. N.; Dey, S. K. Extracellular
signal-regulated kinase is a target of cyclooxygenase-1-peroxisome
proliferator-activated receptor-delta signaling in epithelial ovarian
cancer. Cancer Res. 2007, 67, 5285−5292.
(9) Dore, M.; Cote, L. C.; Mitchell, A.; Sirois, J. Expression of
prostaglandin G/H synthase type 1, but not type 2, in human ovarian
adenocarcinomas. J. Histochem. Cytochem. 1998, 46, 77−84.
(10) Gupta, R. A.; Tejada, L. V.; Tong, B. J.; Das, S. K.; Morrow, J.
D.; Dey, S. K.; DuBois, R. N. Cyclooxygenase-1 is overexpressed and
promotes angiogenic growth factor production in ovarian cancer.
Cancer Res. 2003, 63, 906−911.
(11) Lee, C. Y.; Chen, K. W.; Sheu, F. S.; Tsang, A.; Chao, K. C.; Ng,
H. T. Studies of a tumor-associated antigen, COX-1, recognized by a
monoclonal antibody. Cancer Immunol. Immunother. 1992, 35, 19−26.
(12) Cekanova, M.; Uddin, M. J.; Bartges, J. W.; Callens, A.;
Legendre, A. M.; Rathore, K.; Wright, L.; Carter, A.; Marnett, L. J.
Molecular imaging of cyclooxygenase-2 in canine transitional cell
carcinomas in vitro and in vivo. Cancer Prev. Res. 2013, 6, 466−476.
(27) Ono, N.; Yamamoto, N.; Sunami, A.; Yamasaki, Y.; Miyake, H.
Pharmacological profile of mofezolac, a new non-steroidal analgesic
anti-inflammatory drug. Nihon Yakurigaku Zasshi 1990, 95, 63−81.
(28) Smith, C. J.; Zhang, Y.; Koboldt, C. M.; Muhammad, J.; Zweifel,
B. S.; Shaffer, A.; Talley, J. J.; Masferrer, J. L.; Seibert, K.; Isakson, P. C.
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc.
Natl. Acad. Sci. U.S.A. 1998, 95, 13313−13318.
(29) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.;
Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.;
D
dx.doi.org/10.1021/ml500344j | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX